Day: May 25, 2024

72-week data consistent with disease modification in IgAN, selected as a best-ranked abstract; Rapid and sustained improvements in hematuria over 36 weeks, with resolution in significantly greater percentage of participants than placebo; BRISBANE, Calif., May 25, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data presentations from its Phase 2b ORIGIN trial of atacicept in immunoglobulin A nephropathy (IgAN), showing that atacicept stabilized kidney function through 72 weeks and led to rapid improvements in hematuria. These data were presented at the 61st European Renal Association Congress (ERA24) being held in Stockholm. “For the first...

Luxembourg – 25 May 2024 – Subsea7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a sizeable1 contract by Serica Energy, for the Belinda field development south-east of the Triton FPSO. The Belinda field is operated by Serica Energy and located approximately 190 kilometres east of Aberdeen in the UK Central North Sea, with a water depth of 95 metres. The contract scope includes project management, engineering, procurement, construction and installation (EPCI) of a 5-kilometre 8” production pipeline with a 3” piggy-backed gas lift line and an electro-hydraulic controls (EHC) umbilical. Subsea7’s scope also includes associated subsea structures and tie-ins to the Triton Floating Production Storage & Offloading (FPSO) vessel operated by Dana Petroleum, via an existing production manifold near the Triton riser base...

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2,3 Fabhalta showed a favorable safety profile with no new safety signals1 C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years4-7; currently there are no treatments approved for C3G7-9  Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G1; late-stage development program ongoing across several other rare diseases10-13 Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan)...

In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks1 Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN2-5; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population1 IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies6,7; up to 30% of patients with persistent proteinuria (≥1 g/day) progress to kidney failure within 10 years8 Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action...

TORONTO, May 24, 2024 (GLOBE NEWSWIRE) — MacDonald Mines Exploration Ltd. (TSX-V: BMK, OTC: MCDMF) (“MacDonald Mines” or the “Company”) has discovered inconsistencies in certain assay results from the Scadding gold prospect that were previously publicly announced by way of press releases and which may also have been disclosed or used in certain other disclosure documents, such as the National Instrument 43-101 technical report on the Scadding gold project dated October 18, 2019. Accordingly, the company hereby withdraws all its previously announced assay results for the Scadding gold project and advises that such results and the disclosure that such results are based on should not be relied upon. The company is conducting a detailed review and comparison of the assay results from the Scadding gold project with the company’s...

Toronto, May 24, 2024 (GLOBE NEWSWIRE) — Faircourt Asset Management Inc., as Manager of the Faircourt Fund (NEO:FGX), is pleased to announce the monthly distribution payable on the Shares of the below listed Fund. Faircourt Funds Trading Symbol Distribution Amount (per share/unit) Ex-Dividend Date Record Date Payable Date Faircourt Gold Income Corp. FGX $0.024 May 31, 2024 May 31, 2024 June 14, 2024 Faircourt Asset Management Inc. is the Investment Advisor for Faircourt Gold Income Corp. This press release is not for distribution in the United States or over United States wire services. For further information on the Faircourt Funds, please visit www.faircourtassetmgt.com or please contact 1-800-831-0304. You will usually pay brokerage fees to your dealer if you purchase or sell Shares of the Fund on the NEO Exchange or...